article thumbnail

UK researchers discover new treatment target for atheroschlerosis

Drug Discovery World

The project to develop the new therapeutic, known as IMSET, is being led by Professor Jason Johnson, Professor of Cardiovascular Pathology within the Bristol Medical School. This unique award will allow us to develop a therapeutic to target this novel non-coding RNA, and validate its use in patients with heart disease.”

Treatment 148
article thumbnail

Free webinar today: How is NGS informing oncology drug discovery?

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Register now to learn how NGS is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
article thumbnail

Webinar: Find out how NGS is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
article thumbnail

Next-generation sequencing and oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
article thumbnail

How next-generation sequencing is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
article thumbnail

Revolutionary nanoparticles enable gene-editing in lungs

Drug Target Review

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA 98